In addition, decitabine, an epigenetic modifier, has been shown to enhance PD-L1 expression through DNA hypomethylation, thereby improving the efficacy of PD-L1 blockade in colorectal cancer models.60 The gene discussed is CD274; the disease is colorectal cancer.